Table 3.
Multivariable analysis for 8/8 HLA-MUD HCT vs haploidentical HCT, 2013-2017
| Covariate | No. | HR | 95% Confidence interval | P |
|---|---|---|---|---|
| OS | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| MUD HCT | 1646 | 1.17 | 0.96-1.41 | .11 |
| Remission status | ||||
| CR1 | 1534 | Reference | ||
| CR2+ | 505 | 1.79 | 1.53-2.10 | <.001 |
| Age (y) | <.001 | |||
| 18-29 | 545 | Reference | ||
| 30-39 | 364 | 1.03 | 0.81-1.30 | .82 |
| 40-49 | 391 | 1.38 | 1.11-1.71 | .004 |
| 50-59 | 382 | 1.55 | 1.24-1.93 | <.001 |
| 60-69 | 357 | 1.85 | 1.48-2.31 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 223 | Reference | ||
| White non-Hispanic | 1396 | 0.95 | 0.75-1.21 | .68 |
| Black | 112 | 1.33 | 0.94-1.87 | .11 |
| Asian | 86 | 0.44 | 0.26-0.75 | .002 |
| Other/not specified | 222 | 1.02 | 0.74-1.39 | .92 |
| HCT-CI | .01 | |||
| 0 | 486 | Reference | ||
| 1 | 281 | 1.01 | 0.79-1.30 | .91 |
| 2 | 327 | 1.03 | 0.81-1.30 | .84 |
| 3+ | 939 | 1.25 | 1.04-1.50 | .02 |
| Ph-BCR-ABL1 status | ||||
| Negative | 883 | Reference | ||
| Positive | 766 | 0.82 | 0.70-0.96 | .02 |
| T-ALL/unspecified subtype | 390 | 1.03 | 0.85-1.24 | .77 |
| LFS | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| MUD HCT | 1618 | 1.03 | 0.87-1.22 | .73 |
| Remission status | ||||
| CR1 | 1509 | Reference | ||
| CR2+ | 490 | 1.74 | 1.51-1.99 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 217 | Reference | ||
| White non-Hispanic | 1379 | 0.97 | 0.78-1.19 | .76 |
| Black | 105 | 1.33 | 0.98-1.82 | .07 |
| Asian | 84 | 0.57 | 0.37-0.87 | .01 |
| Other/not specified | 214 | 0.94 | 0.71-1.24 | .67 |
| Conditioning regimen | ||||
| MAC-TBI | 1097 | Reference | ||
| MAC-chemotherapy | 363 | 1.46 | 1.24-1.73 | <.001 |
| RIC/NMA | 539 | 1.61 | 1.39-1.87 | <.001 |
| NRM | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| MUD HCT | 1618 | 1.42 | 1.07-1.89 | .02 |
| Remission status | ||||
| CR1 | 1509 | Reference | ||
| CR2+ | 490 | 1.33 | 1.06-1.67 | .01 |
| Age (y) | <.001 | |||
| 18-29 | 539 | Reference | ||
| 30-39 | 356 | 0.86 | 0.62-1.20 | .37 |
| 40-49 | 382 | 1.30 | 0.97-1.76 | .08 |
| 50-59 | 372 | 1.61 | 1.20-2.15 | .001 |
| 60-69 | 350 | 1.82 | 1.36-2.44 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 217 | Reference | ||
| White non-Hispanic | 1379 | 0.79 | 0.58-1.09 | .15 |
| Black | 105 | 1.04 | 0.63-1.73 | .87 |
| Asian | 84 | 0.35 | 0.16-0.74 | .006 |
| Other/not specified | 214 | 0.98 | 0.66-1.47 | .93 |
| Relapse | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| MUD HCT | 1618 | 0.83 | 0.67-1.03 | .09 |
| Remission status | ||||
| CR1 | 1509 | Reference | ||
| CR2+ | 490 | 2.20 | 1.84-2.64 | <.001 |
| Sex | ||||
| Male | 1168 | Reference | ||
| Female | 831 | 0.81 | 0.68-0.97 | .02 |
| Race/ethnicity | ||||
| White Hispanic | 217 | Reference | ||
| White non-Hispanic | 1379 | 1.04 | 0.78-1.39 | .77 |
| Black | 105 | 1.59 | 1.06-2.37 | .02 |
| Asian | 84 | 0.75 | 0.44-1.26 | .27 |
| Other/not specified | 214 | 0.88 | 0.60-1.29 | .52 |
| Conditioning regimen | ||||
| MAC-TBI | 1097 | Reference | ||
| MAC-chemotherapy | 363 | 1.57 | 1.25-1.98 | <.001 |
| RIC/NMA | 539 | 1.83 | 1.50-2.23 | <.001 |
| aGVHD, grade 2-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| MUD HCT | 1553 | 1.17 | 0.98-1.41 | .09 |
| Conditioning regimen | ||||
| MAC-TBI | 1042 | Reference | ||
| MAC-chemotherapy | 367 | 0.86 | 0.72-1.04 | .11 |
| RIC/NMA | 519 | 0.81 | 0.68-0.95 | .01 |
| aGVHD, grade 3-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| MUD HCT | 1553 | 1.59 | 1.15-2.20 | .005 |
| Race/ethnicity | ||||
| White Hispanic | 217 | Reference | ||
| White non-Hispanic | 1318 | 0.65 | 0.47-0.90 | .009 |
| Black | 109 | 0.90 | 0.53-1.53 | .69 |
| Asian | 80 | 0.29 | 0.12-0.68 | .005 |
| Other/not specified | 205 | 0.67 | 0.43-1.06 | .08 |
| cGVHD | ||||
| MUD vs haploidentical for donor/recipient sex match, other | 1.38 | 1.14-1.68 | .001 | |
| MUD vs haploidentical for donor/recipient sex match, F/M | 2.91 | 1.87-4.52 | <.001 | |
| Remission status | ||||
| CR1 | 1528 | Reference | ||
| CR2+ | 501 | 0.81 | 0.69-0.95 | .009 |
| Donor/recipient sex match | ||||
| Other than F/M | 1707 | Reference | ||
| F/M | 322 | 0.69 | 0.44-1.08 | .10 |